A phase 3b, randomized, double blind, controlled study evaluating the efficacy and safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis subjects, homozygous for F508del mutation - VX18-445-109

Project Details

StatusFinished
Effective start/end date15/09/1930/12/20

Funding

  • Vertex: AUD6,156.00
  • Vertex: AUD14,706.00